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ABSTRACT  
The association between obsessive-compulsive disorder (OCD) and Tourette’s/chronic tic 
disorders (TD/CTD) with autoimmune diseases (AD) is uncertain. In this nationwide study, 
we sought to clarify the patterns of comorbidity and familial clustering of a broad range of 
AD in individuals with OCD and/or TD/CTD and their biological relatives. From a birth 
cohort of 7,465,455 individuals born in Sweden between 1940 and 2007, we identified 
30,082 OCD and 7,279 TD/CTD cases in the National Patient Register and followed them up 
to December 31, 2013. The risk of 40 AD was evaluated in individuals with OCD and/or 
TD/CTD and their first (siblings, mothers, fathers), second (half siblings), and third degree 
(cousins) relatives, compared to population controls. Individuals with OCD and TD/CTD had 
increased comorbidity with any AD (43% and 36%, respectively) and many individual AD. 
The risk of any AD and several individual AD was consistently higher among first-degree 
relatives than among second- and third-degree relatives of OCD and TD/CTD probands. The 
risk of AD was very similar in mothers, fathers, and siblings of OCD probands, whereas it 
tended to be higher in mothers and fathers of TD/CTD probands (compared to siblings). The 
results suggest a familial link between AD in general (i.e., not limited to streptococcus-
related conditions) and both OCD and TD/CTD. Additional mother-specific factors, such as 
the placental transmission of antibodies, cannot be fully ruled out, particularly in TD/CTD.  
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INTRODUCTION  
Immunological factors are increasingly recognized as etiologically important in a range of 
neuropsychiatric disorders, such as autism spectrum disorder,1 schizophrenia,2 or bipolar 
disorder.3 The potential link between immunological factors and psychiatric symptoms has 
been much debated in obsessive-compulsive disorder (OCD) and Tourette’s/chronic tic 
disorders (TD/CTD), due to the still controversial link between group A streptococcus 
infections and the abrupt onset of these psychiatric symptoms in a small group of children.4, 5  
One way to determine if immunological factors are involved in the causation of OCD 
and/or TD/CTD is to examine if there is increased comorbidity and family history of 
autoimmune diseases (AD) in these psychiatric patients. Because AD share some of the same 
risk factors (e.g., cytokine dysfunction, genetic and environmental factors),6-9 tend to coexist 
in the same individuals, and co-aggregate in the same families,10-12 finding an above-chance 
prevalence of AD in patients with OCD and/or TD/CTD and their relatives would support a 
possible role of the immune system in the etiology of these disorders.13 
While the association between rheumatic fever – particularly its neurological 
manifestation, Sydenham’s chorea –, OCD, and TD/CTD has been well established, the link 
with other classic AD is far less clear.13-16 The previous literature has been scarce and 
severely limited by methodological issues, such as the study of small sample sizes mainly 
recruited from specialist clinics, the use of cross-sectional designs, lack of blind assessors, 
lack of control groups, and the use of self-report measures known to have poor psychometric 
properties.13  
The strongest evidence of the association between AD and OCD or TD/CTD 
originates from a handful of family studies suggesting that the mothers of individuals with 
these disorders have elevated rates of AD. In a specialty clinic-based study,17 the mothers of 
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107 children and adolescents with OCD and/or TD/CTD were interviewed regarding their 
history of AD. Nearly 18% of the mothers reported at least one AD; this figure was higher for 
the mothers of children fulfilling likely criteria for PANDAS (Pediatric Autoimmune 
Neuropsychiatric Disorder Associated with Streptococcal Infection) (n=40; 25%), compared 
to the mothers of children with unlikely PANDAS (n=67; 13.4%). A longitudinal population-
based study from Denmark examined the risk of TD (n=2,442) in the offspring of mothers 
with 31 different AD. A maternal history of AD was found in 110 cases, corresponding to an 
increased risk of TD of approximately 22%. The most common maternal AD were ulcerative 
colitis, rheumatoid arthritis, thyrotoxicosis, and multiple sclerosis, although power was 
limited to examine the risk for many of the individual AD.18 In two case-control family 
studies that analyzed the same Brazilian sample using different statistical approaches,19, 20 the 
rate of OCD and related disorders, including tic disorders, was significantly higher among 
first-degree relatives of individuals with rheumatic fever than among first-degree relatives of 
controls (14.7% vs 7.3%),19 and the risk of OCD and related disorders was increased by the 
presence of either rheumatic fever or Sydenham’s chorea in another family member.20 
Conversely, another family study21 found no significant differences in the rates of OCD in 72 
mothers of children and adolescents with inflammatory bowel disease, compared to 44 
mothers of children and adolescents with cystic fibrosis (a non-autoimmune genetic disease). 
Taken together, the results of these family studies support the hypothesis that 
immunological factors may play a role in the etiology of at least some individuals with OCD 
and/or TD/CTD, but these findings require replication in large population-based samples. 
Furthermore, the mechanisms of such association, if confirmed, are yet to be established. One 
possibility is that OCD and TD/CTD share genetic risk factors with AD. If the shared genetic 
risk hypothesis were correct, we would expect that the link between AD and these 
neuropsychiatric syndromes is not limited to mothers but also other first-degree relatives. 
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Further, we would expect that the risks decrease with increasing genetic distance (for 
example, the risks for first-degree relatives should be higher than those for second- and third-
degree relatives). An alternative – and perhaps not mutually exclusive – hypothesis is that 
mothers transmit antibodies to their offspring via the placenta.22, 23 If the maternal 
transmission hypothesis were correct, we would expect that the risk for mothers would be 
significantly higher than the risk for fathers and other first-degree relatives. 
In this study, we analyzed data from a large birth cohort of OCD and TD/CTD cases 
derived from the Swedish population-based registers to address the following questions: 1) 
are patients with OCD and/or TD/CTD more likely to have comorbid AD, compared to 
population controls?; 2) are biological relatives of patients with OCD and/or TD/CTD more 
likely to have AD, compared to relatives of unaffected individuals?; 3) does the familial risk 
decrease with increasing genetic distance?; and 4) do mothers have higher risks than fathers 
or other first-degree relatives?  
 
METHODS 
Study design 
We conducted a population-based birth cohort study to examine the comorbidity and familial 
clustering between AD and OCD and between AD and TD/CTD. We linked information from 
various Swedish national registers using the unique personal identification number, a national 
registration number assigned to each Swedish citizen at birth or immigration.24 These 
national registration numbers are randomly replaced with unique sequence numbers when 
register data is used for research purposes.  
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The Stockholm Regional Ethical Review Board approved the study (2013/862-31/5). 
The requirement for informed consent was waived because the study was register-based and 
the included individuals were not identifiable at any time.  
 
Study cohort 
We selected a cohort of individuals born between 1940 and 2007 and followed them up until 
December 31, 2013. We excluded individuals who died or emigrated before the age of 10 
years. Information about migration and death was derived from the Total Population Register 
and the Cause of Death Register. 
Individuals with OCD and TD/CTD were identified in the National Patient Register 
(NPR) using previously validated algorithms.25 The NPR includes psychiatric inpatient 
discharge diagnoses in Sweden since 1973, recorded according to the International 
Classification of Diseases (ICD) 8th, 9th, and 10th editions.26-29 Since 2001, the register also 
includes information about psychiatric outpatient care.  
The outcomes were diagnoses of 40 widely accepted AD30 in the index person and in 
relatives of an index person identified in the NPR (listed in Supplementary Table 1, 
together with their corresponding ICD codes). Additional analyses were conducted on 
specific AD that were most prevalent in the NPR and had sufficient number of observations 
for analysis (>10 affected individuals). Many of the ICD codes for individual AD in the NPR 
have been subject of validation studies and found to have high validity.29, 32, 33 
Information about relatives was derived from the Multi-Generation Register, which 
contains information about biological parents of an index person. A prerequisite for being 
included in the register is that the index person was born after January 1, 1932 and ever 
registered as living in Sweden after 1960. For immigrants to Sweden, similar information 
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exists for those who became citizens before 18 years of age together with one or both parents. 
The biological father of the offspring is assumed to be the husband of the mother at the time 
of birth or identified “by acknowledgment” for unwed mothers.24    
 
Statistical analyses 
Data managing and analyses were conducted in SAS statistical software version 9.4 (SAS 
Institute, Inc) and Stata IC/14.1. We estimated odds ratios (OR) to quantify the association 
between OCD and TD/CTD and AD with logistic regression analyses. All statistical tests 
employed two-sided 5% level of significance and associated two-sided 95% Wald-type 
confidence intervals (CI) were calculated. We employed the robust variance estimator 
(sandwich estimator) to handle clustering of data. 
 
Individual-level analyses 
First, we estimated the risk of any AD in individuals with a diagnosis of OCD, and separately 
in individuals with a diagnosis of TD/CTD. Individuals born between 1940 and 2007 with a 
lifetime diagnosis of OCD or TD/CTD were considered exposed and those without these 
disorders were considered unexposed. We also examined the risk of individual AD in patients 
with OCD and TD/CTD (those with >10 observations). All analyses adjusted for birth year 
and gender.  
 
Family-level analyses 
We first linked information about biological parents to our cohort and analyzed the risk of 
any AD (and also specific AD) in parents of individuals affected with OCD and TD/CTD 
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compared to parents of unaffected individuals. For the sibling and cousin analyses we used 
the same birth cohort as when studying the individual risk (born between 1940 and 2007). 
Full siblings were defined as individuals who share two biological parents and half siblings 
were defined as individuals who share one parent. Cousin analyses only included full cousins, 
defined as having a common grandfather and grandmother. All analyses adjusted for birth 
year and gender of the index person as well as for birth year of the parent/sibling /cousin. 
 
Sensitivity analyses 
In order to ensure that we studied the independent transmission of these conditions, all family 
analyses were repeated excluding OCD and TD/CTD probands with diagnosed AD as well as 
relatives with either OCD or TD/CTD.  
Additionally, individual-level and family-level analyses for any AD were repeated on 
a subgroup of individuals born between 1963-1983 to ensure complete follow-up from age 10 
to at least age 30, thus avoiding issues with left truncation (i.e., exposure and/or outcome 
happening before the register started and thus missing) and right censoring (i.e., study ending 
when individuals were still young). 
 We also repeated the individual- and family-level analyses for any AD excluding 
individuals diagnosed before 2001, date from which outpatients were first included in the 
register, to ensure that more severe patients (i.e., inpatients) were not biasing the results. 
 
RESULTS 
Study cohort 
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The cohort included a total of 7,465,455 unique individuals of which 30,082 had a diagnosis 
of OCD and 7,279 had a diagnosis of TD/CTD. Moreover, our cohort included 7,416,593 
individuals with information about both biological parents, 10,670,459 full sibling pairs, 
1,420,623 maternal half-sibling pairs, 1,841,737 paternal half-sibling pairs, and 25,856,102 
cousin pairs. 
 
Individual-level analysis 
Individuals with OCD had a 43% increased risk of any AD, compared to individuals without 
OCD (OR=1.43, 95% CI=1.37-1.49; Table 1). In the analyses of individual AD, the risk was 
significantly elevated for Sjögren’s syndrome (94% increase), celiac disease (76%), Guillain-
Barré syndrome (71%), Crohn’s disease (66%), Hashimoto’s thyroiditis (59%), type 1 
diabetes mellitus (56%), scarlet fever (52%), idiopathic thrombocytopenic purpura (51%), 
ulcerative colitis (41%), multiple sclerosis (41%), and psoriasis vulgaris (32%). Other AD 
(e.g., systemic lupus erythematosus or acute disseminated encephalomyelitis) were also 
associated with OCD, but power was limited, resulting in wide CI.  
Similarly, individuals with TD/CTD were 36% more likely to be affected with any 
AD than members of the same cohort without TD/CTD (OR=1.36, 95% CI=1.22-1.51; Table 
1). In the analyses of individual AD, the highest risk was found for Hashimoto’s thyroiditis 
(106% increase), celiac disease (67%), scarlet fever (62%), type 1 diabetes mellitus (37% 
increase), and psoriasis vulgaris (33% increase). Other AD, such as Chrohn’s disease or 
vitiligo, were also associated with TD/CTD, but CI were wide due to limited statistical 
power. 
 
Family-level analysis 
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When examining the risk of any AD in relatives of index persons with OCD, compared to 
relatives of persons who did not have OCD, we found that the association was strongest and 
statistically significant among first-degree relatives (Table 2). Mothers, fathers, and full 
siblings of individuals with OCD were each significantly more likely to be affected with an 
AD. The risk was marginally higher among mothers (17% increase) and siblings (16% 
increase) than among fathers (8% increase), but CI overlapped. The associations between 
OCD and AD in second-degree relatives (maternal or paternal half siblings) or in cousins 
were lower than for first-degree relatives and none were statistically significant (Table 2). 
Family-level analyses of individual AD followed the same general pattern (Supplementary 
Table 2). 
Individuals with TD/CTD were statistically significantly more likely to have a first-
degree relative with any AD (Table 2). The effect was highest among mothers of individuals 
diagnosed with TD/CTD (40% increased risk), followed by fathers (31% risk) and siblings 
(17% risk), but CI overlapped. Furthermore, second- and third-degree relatives of individuals 
with TD/CTD did not have a significantly elevated risk of AD (Table 2). Family-level 
analyses of individual AD followed the same general pattern (Supplementary Table 3). 
In an exploratory post-hoc analysis, we examined if individuals with both OCD and 
TD/CTD (OCD + TD/CTD; n= 1,276) had similar comorbidity and familial risks of AD. The 
results revealed that these individuals had similar comorbidity (OR=1.48) to that reported in 
the main analyses above. The familial estimates were similar to those of TD/CTD probands, 
with one exception: the risk of AD in siblings was somewhat higher amongst OCD + 
TD/CTD probands (OR=1.38). However, these results need to be interpreted cautiously given 
the small sample size and wide confidence intervals (only 99 siblings of OCD + TD/CTD 
probands had at least one AD; Supplementary Table 4). 
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Sensitivity analyses 
A similar pattern of results was obtained in sensitivity analyses excluding probands with any 
AD as well as relatives with either OCD or TD/CTD (Figure 1; Supplementary Table 5) in 
the sub-cohort of patients born from 1963 to 1983 (Supplementary Table 6) and in the sub-
cohort of patients diagnosed from 2001 (Supplementary Table 7). 
 
DISCUSSION  
In this total-population, multigenerational family study we found that both OCD and 
TD/CTD are highly comorbid with a broad range of AD across all organ systems. 
Specifically, individuals with OCD were 43% more likely, and individuals with TD/CTD 
36% more likely, to have any comorbid AD, compared to unaffected individuals from the 
general population.  
In patients with OCD, most individual AD showed an increased comorbidity rate, but 
the association was strongest for Sjögren’s syndrome (94% increase), celiac disease (76%), 
Guillain-Barré syndrome (71%), Crohn’s disease (66%), Hashimoto’s thyroiditis (59%), type 
1 diabetes mellitus (56%), scarlet fever (52%), idiopathic thrombocytopenic purpura (51%), 
ulcerative colitis (41%) multiple sclerosis (41%), and psoriasis vulgaris (32%). Similarly, in 
TD/CTD, many individual AD showed an association but, due to modest statistical power for 
some of the rarest AD, this only reached statistical significance for Hashimoto’s thyroiditis 
(106% increase), celiac disease (67%), scarlet fever (62%), type 1 diabetes mellitus (37%), 
and psoriasis vulgaris (33%). These results expand our previous knowledge on the subject – 
as previous studies had been limited by a range of methodological issues13 – and suggest that 
there is a clear association between both OCD and TD/CTD and AD in general, which is not 
limited to streptococcal-related conditions. 
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The family analyses revealed significantly elevated risk of AD in first-degree relatives 
of both OCD and TD/CTD patients, but not in second- or third-degree relatives. The 
magnitude of the results was highest for first-degree relatives of TD/CTD probands. The 
results were unchanged when we excluded OCD and TD/CTD probands with diagnosed AD, 
as well as relatives with either OCD or TD/CTD, and in various sensitivity analyses. While 
our design does not allow us to confidently rule out shared environmental factors, the pattern 
of results is compatible with a possible shared genetic etiology between OCD and TD/CTD 
and AD, at least in some patients. First, the association was only statistically significant 
amongst first-degree relatives. Second, siblings of probands had similar (OCD) or lower 
(TD/CTD) risks of AD than mothers and fathers (they all share about 50% of the genes) 
despite siblings sharing more of the environment (siblings are born in the same family, during 
a similar period of time, and grow up in the same household). Furthermore, maternal and 
paternal half-siblings (both sharing 25% of genes but paternal half-siblings sharing less 
environment, as >90% of Swedish children continue living with their mothers after a 
divorce)34 had very similar risks of AD. Consistent with a potential genetic mechanism, a 
recent study using publicly available genome-wide association (GWAS) data to explore the 
genetic correlations between a range of psychiatric and medical phenotypes with 
immunological and/or inflammatory disorders35 revealed significant positive genetic 
correlations (uncorrected for multiple testing ±standard error) between OCD and celiac 
disease (rg=0.39±0.18) and ulcerative colitis (rg=0.29±0.09), and negative correlations with 
type 1 diabetes mellitus (rg=-0.28±0.10).35 It should be noted that current published GWAS 
for OCD36, 37 and TD,38 as well as some AD, are underpowered to detect genome-wide 
significant associations and much larger studies are needed. For example, it remains unclear 
whether OCD or TD/CTD are associated with variation in the major histocompatibility 
complex region on chromosome 6, which has a major influence on risk for many AD. 
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Future molecular genetic studies should focus on collection of DNA from large 
numbers of OCD and TD/CTD cases with rich clinical and environmental risk factor 
information (e.g., personal and family history of AD, documented temporality between 
infection and symptom onset). At least one study of this type is currently ongoing in 
TD/CTD.39, 40 In addition, comparison of genetic markers in patients with vs without 
additional neurological or immunological symptoms (PANS [Pediatric Acute-onset 
Neuropsychiatric Syndrome]/PANDAS) may yield mechanistic insight. Given the complexity 
of these psychiatric and immunological traits, well-powered analyses are key to robust 
findings. An excellent demonstration of this comes from a recent analysis41 of GWAS data 
for more than 60,000 cases and controls representing three adult psychiatric disorders: 
schizophrenia, major depression, and bipolar disorder. The authors searched for biological 
pathways enriched for psychiatric risk variants and found that multiple immune signaling 
pathways were among the most robustly associated, providing a mechanistically-informative 
link between genetic and epidemiological studies for these disorders.  
Mothers, fathers, and full siblings of individuals with OCD and TD/CTD were each 
more likely to be affected with an AD, compared to unaffected individuals from the general 
population. In some analyses, particularly in TD/CTD, the risk was slightly higher among 
mothers than among fathers and siblings, but these differences were not statistically 
significant, as indicated by the overlapping confidence intervals. These findings confirm and 
extend previous studies that focused exclusively on mothers,17, 18 and suggest that, while 
maternal-specific factors cannot be fully ruled out, particularly in TD/CTD, such as the 
placental transmission of antibodies to the offspring – which may in turn activate the immune 
system in the child and alter normal brain development18 – genetic factors appear to be 
important. Given the increased attention to maternal immune activation in neuropsychiatric 
disorders,42, 43 future studies could examine if maternal infection and active AD during 
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pregnancy are associated with increased risk of OCD and TD/CTD in their offspring and how 
this risk varies as a function of interaction with genetic and other environmental risk factors. 
 
Strengths and limitations 
The main strengths of this study include the uniquely large population-based cohorts of OCD 
and TD/CTD patients, which generally provided sufficient power to address the primary 
study questions, the inclusion of different kinds of biological relatives with differing degrees 
of shared genetic liability and shared environment, the long-term perspective (most previous 
studies have been cross-sectional), and the fact that the Swedish ICD codes for OCD, 
TD/CTD, and many of the AD have been formally validated.25, 29, 32, 33  
The results need to be interpreted in light of some limitations. First, despite the large 
cohorts, power was still limited for several of the individual AD, particularly streptococcus-
related diseases (such as rheumatic fever with or without chorea), which means that we could 
not calculate some of the specific risks or these resulted in less precise estimates (wide CI). 
Second, because the Swedish versions of ICD-8 and ICD-9 do not differentiate between type 
1 and type 2 diabetes mellitus, we only included individuals diagnosed with type 1 diabetes 
mellitus according to ICD-10, resulting in the exclusion of older cases diagnosed before ICD-
10 was introduced in Sweden (1997). Third, our cohorts do not represent the totality of all 
OCD and TD/CTD patients in Sweden; many sufferers do not seek help, the coverage of the 
register before 2001 is incomplete, and patients diagnosed by general practitioners and non-
medical specialists are not included. In contrast, AD may be more likely to be seen by 
specialist physicians in Sweden, resulting in better coverage in the patient register. 
 
Clinical implications 
 15
It may be sensible to routinely screen for and document comorbid AD and family history of 
AD in all patients with OCD and TD/CTD, particularly – but not exclusively – in those 
presenting with the constellation of symptoms commonly referred to as PANS or PANDAS. 
Long-term follow-up of these patients may provide useful clues regarding their prognosis, 
compared to patients without a personal or familial link to AD. Whether patients with an AD 
link respond differently or preferentially to conventional evidence-based treatments is another 
interesting question for the future. As knowledge advances, it may be possible to identify 
robust biomarkers to help guide the clinical management of those patients.  
 
Conclusion 
The results suggest a familial, potentially genetic link between both OCD and TD/CTD and a 
broad range of AD, which is not limited to streptococcus-related conditions. At present, we 
cannot fully rule out shared environmental effects or additional mother-specific factors, such 
as the placental transmission of antibodies to their offspring, particularly in TD/CTD. 
Screening for AD in these patients and their relatives would make good clinical sense. 
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Figure 1. Sensitivity analyses. Risk (ORs and 95% CI) of any AD in probands and relatives 
of probands with OCD (panel A) and TD/CTD (panel B). Analyses exclude any AD amongst 
probands as well as OCD or TD/CTD in the relatives (full data available in Supplementary 
Table 5).  
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Footnotes: Gray shapes = probands; red shapes = first-degree relatives, green shapes = 
second-degree relatives, yellow shapes = third-degree relatives. 
Abbreviations: AD = autoimmune diseases; CI = confidence interval; CTD = chronic tics 
disorder; OCD = obsessive-compulsive disorder; OR = odds ratio; TD = Tourette’s disorder. 
Table 1. Within individual analyses: Comorbidity patterns between OCD and AD (top half of 
the table) and between TD/CTD and AD (bottom half of the table).a 
a Specific autoimmune diseases with 10 or fewer observations per cell are not reported due to 
limited statistical power and to prevent possible identification of individuals. 
Footnotes: Statistically significant findings are marked in bold. 
AD AD in OCD 
OCD 
probands 
AD in non-
OCD 
Non-OCD 
probands OR (95% CI) p-value 
Any AD 2,448 30,082 472,874 7,435,373 1.43 (1.37-1.49) <0.01 
Crohn’s disease 192 27,826 29,245 6,991,744 1.66 (1.44-1.91) <0.01 
Ulcerative colitis 258 27,892 48,054 7,010,553 1.41 (1.24-1.59) <0.01 
Graves' disease 13 27,647 3,932 6,966,431 1.22 (0.70-2.10) 0.48 
Hashimoto's thyroiditis 78 27,712 10,142 6,972,641 1.59 (1.27-1.98) <0.01 
Celiac disease 327 27,961 39,231 7,001,730 1.76 (1.58-1.97) <0.01 
Multiple sclerosis 88 27,722 18,249 6,980,748 1.41 (1.14-1.74) <0.01 
Systemic lupus 
erythematosus 
31 27,665 6,019 6,968,518 1.43 (1.00-2.04) 0.05 
Acute disseminated 
encephalomyelitis 
24 27,658 4,172 6,966,671 1.45 (0.97-2.16) 0.07 
Rheumatoid arthritis 97 27,731 30,249 6,992,748 1.17 (0.96-1.43) 0.12 
Psoriasis vulgaris 480 28,114 107,522 7,070,021 1.32 (1.20-1.44) <0.01 
Type 1 diabetes 
mellitus 
381 28,015 74,063 7,036,562 1.56 (1.41-1.72) <0.01 
Vitiligo 54 27,688 9,727 6,972,226 1.25 (0.96-1.64) 0.10 
Idiopathic 
thrombocytopenic 
purpura 
41 27,675 6,277 6,968,776 1.51 (1.10-2.06) <0.01 
Scarlet fever 32 27,666 5,967 6,968,466 1.52 (1.08-2.16) 0.02 
Henoch-Schonlein 
purpura 
48 27,682 10,603 9,673,102 0.98 (0.74-1.30) 0.88 
Guillain-Barré 
syndrome 
16 27,650 2,936 6,965,435 1.71 (1.04-2.80) 0.03 
Sjögren's syndrome 39 27,673 7,757 6,970,256 1.94 (1.41-2.66) <0.01 
AD AD in TD/CTD 
TD/CTD 
probands 
AD in non-
TD/CTD 
Non-TD/CTD 
probands OR (95 % CI) p-value 
Any AD 408 7,279 474,914 7,458,176 1.36 (1.22-1.51) <0.01 
Crohn’s disease 22 6,893 29,415 7,012,677 1.22 (0.80-1.85) 0.36 
Ulcerative colitis 26 6,897 48,286 7,031,548 0.99 (0.67-1.46) 0.96 
Hashimoto's thyroiditis 11 6,882 10,209 6,993,471 2.06 (1.14-3.73) 0.02 
Celiac disease 79 6,950 39,479 7,022,741 1.67 (1.34-2.09) <0.01 
Psoriasis vulgaris 74 6,945 107,928 7,091,190 1.33 (1.06-1.68) 0.01 
Type 1 diabetes 
mellitus 
76 6,947 74,368 7,057,630 1.37 (1.10-1.72) <0.01 
Vitiligo 12 6,883 9,769 6,993,031 1.17 (0.66-2.07) 0.58 
Scarlet fever 17 6,888 5,982 6,989,244 1.62 (1.01-2.62) 0.05 
Henoch-Schonlein 
purpura 
17 6,888 10,634 6,993,896 1.04 (0.65-1.67) 0.87 
Abbreviations: AD = autoimmune diseases; CI = confidence interval; CTD = chronic tics 
disorder; OCD = obsessive-compulsive disorder; OR = odds ratio; TD = Tourette’s disorder. 
Table 2. Family analyses: Risk of any AD in relatives of probands with OCD (top half of the 
table) and relatives of probands with TD/CTD (bottom half of the table).  
 
 AD in 
relatives 
of OCD- 
probands 
Relatives 
of OCD 
probands 
AD in 
relatives of 
non-OCD 
probands 
Relatives of 
non-OCD 
probands 
OR (95% CI) p-value 
Siblings 2,709 40,356 693,544 10,630,103 1.16 (1.12-1.21) <0.01 
Mothers 3,404 29,492 767,675 7,387,101 1.17 (1.13-1.21) <0.01 
Fathers 2,381 29,492 541,109 7,387,101 1.08 (1.04-1.13) <0.01 
Maternal half siblings 548 8,617 89,075 1,412,006 1.08 (0.98-1.18) 0.11 
Paternal half siblings 603 10,531 115,433 1,831,206 0.99 (0.91-1.07) 0.76 
Cousins 7,469 134,159 1,398,239 25,721,943 1.02 (1.00-1.05) 0.07 
 AD in 
relatives 
of 
TD/CTD 
probands 
Relatives 
of 
TD/CTD 
probands 
AD in 
relatives of 
non-
TD/CTD 
probands
Relatives of 
Non-TD/CTD 
probands 
OR (95 % CI) p-value 
Siblings 448 8,352 695,805 10,662,107 1.17 (1.06-1.31) <0.01 
Mothers 794 7,083 770,285 7,409,510 1.40 (1.30-1.51) <0.01 
Fathers 566 7,083 542,924 7,409,510 1.31 (1.20-1.42) <0.01 
Maternal half siblings 146 2,730 89,477 1,417,893 1.11 (0.93-1.33) 0.23 
Paternal half siblings 169 3,090 115,883 1,838,647 1.09 (0.93-1.28) 0.29 
Cousins 1,624 31,737 1,404,084 25,824,365 1.05 (1.00-1.11) 0.06 
 
Footnotes: Statistically significant findings are marked in bold. 
Abbreviations: AD = autoimmune diseases; CI = confidence interval; CTD = chronic tics 
disorder; OCD = obsessive-compulsive disorder; OR = odds ratio; TD = Tourette’s disorder. 
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